Andere talen Werewolf Therapeutics, Inc.

Aandelen

HOWL

US95075A1079

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5,87 ^USD	+0,51%		+15,78%	+52,07%

05/04	Werewolf Therapeutics, Inc. presenteert preklinische resultaten die anti-tumor effecten aantonen van pro-inflammatoire cytokine therapeutica	CI
03/04	WEREWOLF THERAPEUTICS, INC. : JMP Securities geeft koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting	05/04
Werewolf Therapeutics, Inc. Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics	05/04
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting	04/04
Werewolf Therapeutics' Q4 Net Loss Narrows	07/03
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	07/03
Werewolf Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference	06/03
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024	05/03
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook	08/01
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors	04/01
Werewolf Therapeutics, Inc. Appoints Michael Atkins to its Board of Directors	04/01
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference	22/11
North American Morning Briefing : Stocks Seen -2-	15/11
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	14/11
Werewolf Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Sector Update: Health Care Stocks Stronger Late Afternoon	03/11
Sector Update: Health Care	03/11
Top Midday Gainers	03/11
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer?s 38th Annual Meeting	03/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Werewolf Therapeutics, Inc.

Aandelen

HOWL

US95075A1079

Andere talen

Filters